Skip to main content
Smart Investors Daily
EL

OTC · ELTP

Elite Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.30

Down-$0.01 (-1.64%)

Updated Aug 20, 2026, 2:57 AM

SID Score

4.5/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
554.52M
P/E ratio
39.95
Dividend yield
0.00%
52-week range
— – —
Volume
100.06K
Avg. volume
816.74K

Price performance

ELTP price history

1M range · 0 trading sessions · Daily adjusted prices

ELTP does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ELTP news

The latest Smart Investors Daily articles mentioning ELTP.

ELTP research

Overview

Company profile and research snapshot.

Company profile

ELITE PHARMS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 4, 2026

Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL

Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat Parkinson's...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.